Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why This 1 Growth Stock Should Be On Your Watchlist

Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Exelixis (EXEL)

Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics.

Invest in Gold

Thor Metals Group: Best Overall Gold IRA

Learn More

Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase

Learn More

American Hartford Gold: #1 Precious Metals Dealer in the Nation

Learn More Powered by Money.com - Yahoo may earn commission from the links above.

EXEL is a Zacks Rank #2 (Buy) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected to grow 32% year-over-year for the current fiscal year, with sales growth of 7.9%.

10 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.33 to $2.64 per share. EXEL boasts an average earnings surprise of 48.6%.

Looking at cash flow, Exelixis is expected to report cash flow growth of 135.6% this year; EXEL has generated cash flow growth of 10.8% over the past three to five years.

EXEL should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research